Ocrelizumab, a new B-cell–targeted therapy for multiple sclerosis (MS), demonstrated efficacy in the treatment of relapsing and primary progressive MS (PPMS), according to a recent literature review, and is the first therapy approved for patients with PPMS. A comprehensive literature search was conducted using search terms “ocrelizumab” and “multiple sclerosis” using the date range of 1946 through October 2017. Investigators found:
- A phase II trial established 600 mg intravenously every 6 months as the preferred dosing schedule.
- 2 phase III trials evaluated the efficacy of ocrelizumab in patients with relapsing remitting MS, and individual and pooled analysis demonstrated a significant reduction in annualized relapse rate, disability progression at 12 weeks, and gadolinium-enhancing lesions on magnetic resonance imaging (MRI).
- Patients with PPMS were evaluated in a third phase III trial, which showed a significant decrease in disease progression at 12 weeks and volume of T2-weighted lesions on MRI.
Stahnke AM, Holt KM. Ocrelizumab: A new B-cell therapy for relapsing remitting and primary progressive multiple sclerosis. [Published online ahead of print December 12, 2017]. Ann Pharmacother. doi:10.1177/1060028017747635.
This Week's Must Reads
Higher Cortisol Linked with Lower Brain Volume, Neurology; ePub 2018 Oct 24; Echouffo-Tcheugui, et al
Ischemic Stroke Transfers in the Northeastern US, J Stroke Cerebrovasc Dis; ePub 2018 Oct 30; Zachrison, et al
Predictors of Recurrent Hospitalizations Post-TIA, J Stroke Cerebrovasc Dis; ePub 2018 Oct 17; Yousufuddin, et al
Sleep Apnea Associated with Less Healthful Diet, Sleep; ePub 2018 Oct 22; Reid, Maras, Shea, et al
Hypertension, Obesity, Cognitive Decline Examined , Alzheimers Dement; ePub 2018 Oct 24; Clark, et al
Must Reads in Multiple Sclerosis
No Link Between Overall Diet, MS Risk in Women, Mult Scler; ePub 2018 Oct 23; Rotstein, et al
Pubertal Onset of MS and Relapses in Boys, Mult Scler Relat Disord; ePub 2018 Oct 22; Young, et al
FLAIR Signal and Venous Abnormalities Linked in MS, AJNR Am J Neuroradiol; ePub 2018 Oct 18; Rogers, et al
Diabetes and Anxiety Affect Cognition in MS, Mult Scler Relat Disord; ePub 2018 Oct 23; Marrie, et al
Illness Intrusiveness on Intimacy in Persons with MS, Qual Life Res; 2018 ePub 2018 Oct 17; Neto, et al